Transforming Your Capabilities.
We provide the seamless integration of GI research into your practice to broaden your offerings, enhance care for your patients, and increase your support for referring physicians.
Transforming Your Research.
With premier integrated research partnerships across the country, we can offer a program supported by embedded study teams, leading to greater patient access at the point of care.
Transforming Your Outlook.
We are studying NASH and other diseases with the aim of developing new therapies to address growing problems and improve your overall health.
Let’s work together.
We’re taking on NASH with strong research partnerships and innovative approaches that leverage a proven platform. You can be part of it.
New research aimed at developing a first-in-class dual agonist
New research aimed at developing a first-in-class dual agonist that targets all three key drivers of NASH – steatosis, inflammation, and fibrosis.
ObjectiveGI Collaborates with Clinical Research IO
ObjectiveGI Collaborates with Clinical Research IO to Launch eSource Direct Data Capture Research Capabilities at the Point-of-Care
New drug for treating fatty liver disease
A new drug for treating fatty liver disease is currently being reviewed by the FDA.
weight loss with ESG
Landmark research shows 15% sustainable weight loss with ESG which is associated with improvement in NASH, diabetes and cardiovascular disease.